Immunophenotyping invasive breast cancer: paving the road for molecular imaging
Open Access
- 13 June 2012
- journal article
- Published by Springer Nature in BMC Cancer
- Vol. 12 (1) , 240
Abstract
Background: Mammographic population screening in The Netherlands has increased the number of breast cancer patients with small and non-palpable breast tumors. Nevertheless, mammography is not ultimately sensitive and specific for distinct subtypes. Molecular imaging with targeted tracers might increase specificity and sensitivity of detection. Because development of new tracers is labor-intensive and costly, we searched for the smallest panel of tumor membrane markers that would allow detection of the wide spectrum of invasive breast cancers. Methods: Tissue microarrays containing 483 invasive breast cancers were stained by immunohistochemistry for a selected set of membrane proteins known to be expressed in breast cancer. Results: The combination of highly tumor-specific markers glucose transporter 1 (GLUT1), epidermal growth factor receptor (EGFR), insulin-like growth factor-1 receptor (IGF1-R), human epidermal growth factor receptor 2 (HER2), hepatocyte growth factor receptor (MET), and carbonic anhydrase 9 (CAIX) 'detected' 45.5% of tumors, especially basal/triple negative and HER2-driven ductal cancers. Addition of markers with a 2-fold tumor-to-normal ratio increased the detection rate to 98%. Including only markers with >3 fold tumor-to-normal ratio (CD44v6) resulted in an 80% detection rate. The detection rate of the panel containing both tumor-specific and less tumor-specific markers was not dependent on age, tumor grade, tumor size, or lymph node status. Conclusions: In search of the minimal panel of targeted probes needed for the highest possible detection rate, we showed that 80% of all breast cancers express at least one of a panel of membrane markers (CD44v6, GLUT1, EGFR, HER2, and IGF1-R) that may therefore be suitable for molecular imaging strategies. This study thereby serves as a starting point for further development of a set of antibody-based optical tracers with a high breast cancer detection rate.Keywords
This publication has 47 references indexed in Scilit:
- Molecular subtyping of male breast cancer by immunohistochemistryLaboratory Investigation, 2012
- A Novel Fluorescent Imaging Agent for Diffuse Optical Tomography of the Breast: First Clinical Experience in PatientsMolecular Imaging and Biology, 2009
- FISH and immunohistochemical status of the hepatocyte growth factor receptor (c-Met) in 184 invasive breast tumorsBreast Cancer Research, 2009
- Human Breast Cancer Tumor Models: Molecular Imaging of Drug Susceptibility and Dosing during HER2/neu-targeted TherapyRadiology, 2008
- New Technologies for Human Cancer ImagingJournal of Clinical Oncology, 2008
- Affibody Molecules for In vivo Characterization of HER2-Positive Tumors by Near-Infrared ImagingClinical Cancer Research, 2008
- Radioguided occult lesion localization (ROLL) versus wire‐guided lumpectomy for non‐palpable breast lesions: A randomized prospective evaluationJournal of Surgical Oncology, 2008
- Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological dataJournal of Clinical Pathology, 2006
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences, 2001
- pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐upHistopathology, 1991